Immunotherapy with antibody delivery technology for brain tumors (glioblastoma)

It arises from glial cells, the brain cells that support and nourish neurons. It progresses very quickly and has a poor 5-year survival prognosis.

Immune checkpoints (ICs) are the normal part of the immune system and play a role in preventing the immune response from becoming so strong that healthy cells in the body are destroyed. Awarded by Professor Tasuku Honjo of Kyoto University Nobel Prize In physiology or medicine in 2018 for this discovery.

Antibody delivery technology

But these are ICI has not proven effective against a variety of cancers, including brain metastases. Primarily, the blood tumor barrier, which suppresses the accumulation of ICI in brain tumors, ultimately causes life-threatening immune-related adverse events.

As a result, this study has developed a technique to strongly increase the accumulation of ICI in brain tumors and achieve both therapeutic efficacy and safety.

The team verified the results In an orthotopic glioblastoma model, a single dose of 15% modified avelumab (low dose of 1.5 mg / kg) reached a complete response rate of 60%. Has long-term immunological memory.

In addition, the technology also suppressed immune-related adverse events in avelumab. The amount of ICI accumulated in the brain tumor site is 33 times that of normal brain tissue, indicating that brain tumors are highly selective.

Therefore The modified antibody achieved a strong antitumor effect on the preclinical GBM model. This emphasizes that this study is expected to apply these results to the prevention of GBM recurrence, despite the fact that GBM is a malignant tumor that recurs frequently.

Source: Medindia

Back to top button